Clinical Trial

Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure

Study acronym: SAFE-LAAC
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 11, 2023 (before its estimated June 23, 2025 completion). Its status may not reflect the trial's current state.
Summary
SAFE-LAAC Trial has been designed to gather data on the most optimal strategy of antiplatelet therapy after transcatheter left atrial appendage occlusion with Amplatzer or WATCHMAN device
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2018-02-19; most recent amendment 2023-07-10.
Trial Details
NCT Number NCT03445949
Lead Sponsor National Institute of Cardiology, Warsaw, Poland
Collaborators: Medical Research Agency, Poland
Conditions Atrial Fibrillation
Enrollment 200 participants
Start Date 2018-01-23
Primary Completion 2025-06-23 (estimated)
Study Completion 2027-06-23 (estimated)
Updated on ClinicalTrials.gov 2023-07-11